OXURION NV (OXUR.BR)

BE0974487192 - Common Stock

0.269  +0.01 (+3.46%)

Fundamental Rating

0

OXUR gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 75 industry peers in the Biotechnology industry. OXUR may be in some trouble as it scores bad on both profitability and health. OXUR does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OXUR has reported negative net income.
OXUR had a negative operating cash flow in the past year.
In the past 5 years OXUR always reported negative net income.
OXUR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -249.85%, OXUR is doing worse than 92.86% of the companies in the same industry.
Industry RankSector Rank
ROA -249.85%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

OXUR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

OXUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for OXUR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -37.44, we must say that OXUR is in the distress zone and has some risk of bankruptcy.
OXUR has a Altman-Z score of -37.44. This is amonst the worse of the industry: OXUR underperforms 90.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -37.44
ROIC/WACCN/A
WACC7.73%

2.3 Liquidity

A Current Ratio of 0.08 indicates that OXUR may have some problems paying its short term obligations.
OXUR has a worse Current ratio (0.08) than 98.57% of its industry peers.
OXUR has a Quick Ratio of 0.08. This is a bad value and indicates that OXUR is not financially healthy enough and could expect problems in meeting its short term obligations.
OXUR has a worse Quick ratio (0.08) than 98.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.08

More info and screens

0

3. Growth

3.1 Past

OXUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.54%, which is quite impressive.
OXUR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -83.69%.
Measured over the past years, OXUR shows a very negative growth in Revenue. The Revenue has been decreasing by -45.20% on average per year.
EPS 1Y (TTM)98.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.77%
Revenue 1Y (TTM)-83.69%
Revenue growth 3Y-49.79%
Revenue growth 5Y-45.2%
Sales Q2Q%-99.44%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OXUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OXUR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OXURION NV

EBR:OXUR (12/20/2024, 7:00:00 PM)

0.269

+0.01 (+3.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-30 2024-09-30
Earnings (Next)N/A N/A
Inst Owners0.22%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap691.33K
Analysts42.22
Price Target0.27 (0.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.23
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-32.56
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.8
FCFYN/A
OCF(TTM)-1.8
OCFYN/A
SpS0.03
BVpS-5.76
TBVpS-5.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -249.85%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.08
Altman-Z -37.44
F-Score2
WACC7.73%
ROIC/WACCN/A
Cap/Depr(3y)2.17%
Cap/Depr(5y)3.36%
Cap/Sales(3y)4.38%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.77%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-83.69%
Revenue growth 3Y-49.79%
Revenue growth 5Y-45.2%
Sales Q2Q%-99.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y82.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.85%
OCF growth 3YN/A
OCF growth 5YN/A